<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110628006907N14</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-03-11</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Effects of umbilical cord derived mesenchymal stem cells injection in the treatment of children with cerebral palsy</public_title>
      <acronym>MSCCP</acronym>
      <scientific_title>A Randomized Clinical Trial Phase I&amp;II of 3 Times Intratechal Injections of Umbilical Cord Derived Mesenchymal cells in Children with Spastic Cerebral Palsy 2-14 years old in comparison with control group</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-04-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/45965</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: Designing of 3 injection of stem cells with defined interval in intervention group - including of hemiparetic CP in the study, Randomization description: The patients are randomly allocated into two  groups of intervention and control using a balanced block randomization technique. To do that, they were divided into blocks of 6 and 9. All subjects randomly allocated with online randomization software to generate random-number sequences. {Sealed Envelope Ltd. 2015. Create a blocked randomization list. [Online] Available from: https://www.sealedenvelope.com/simple-randomiser/v1/lists [Accessed 15 Dec 2015]}. Coordinator and Physician responsible for assessing inclusion / exclusion criteria and registering individuals are blind, Blinding description: As this study designed as double blind , In the control group after insertion of the needle into the skin with an appearance of simulating of  lumbar puncture no injection were done without the awareness of the patients or their parents and clinical evaluators . At the end of the study if safety and effectiveness of cell therapy will be proved , for ethical consideration cell therapy will be performed for control group .</study_design>
      <phase>1-2</phase>
      <hc_freetext>Spastic Cerebral Palsy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group  :  CP patients receiving  ،three  intrathecal injection of 20 millions  allogenic mesenchymal stem cellls derived from umbilical cord ,   prepared by Cell Thec Pharmed Company. Interval of injections is every 2 weeks .  Intrathecal injection will be done under anesthesia via lumbar puncture . After taking 3-5  milliliter of cerebrospinal fluid ,  2 milliliter prepared stem cells will be injected with a syringe . The patient will be admitted for one day for monitoring of probable adverse reactions  . One year followup and evaluation with regular similar rehabilitative therapy will be done . Intervention 2: Control group  : CP  patients without injection , that after insertion of needle into the skin without entering into the cerebrospinal fluid space , needle will be withdrawn without any injection and only with an appearance of simulation of lumbar puncture without the awareness of the patient or their parents. The patient will be admitted one day for monitoring of probable adverse reaction . One year followup and evaluation with regular similar rehabilitative therapy will be done .</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All collected deidentified IPD can be shared

When:
6 months after publication

To whom:
People working in academic institutions and people working in businesses

Conditions:
Planning of similar studies in other academic centers

Where to obtain:
Email address

How to obtain:
After request during the 1-2 months

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Anahita Majmaa</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Children's Medical Center Hospital , No 62 , Gharib Street , End of Keshavarze Blvd , Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733151</zip>
        <telephone>+98 21 6612 9252</telephone>
        <email>majmaaa911@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahmoud Reza Ashrafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Children's Medical Center , No 62 , Gharib Street , End of Keshavarz Blvd , Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733151</zip>
        <telephone>+98 21 6612 9252</telephone>
        <email>mr_ashrafi@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Spastic cerebral palsy (Dip , Quadri, Hemiparetic )                                                            Ages between 2 - 14 years                                                                                                                   Gross motor function classification (GMFC)  2 -4                                                                          No seizure disorder or with controlled seizure                        Acquired brain MRI finding compatible with CP                                                                                  Informed consent of parents</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>14 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Normal brain MRI                                                                                                           Progressive neurological  diseases                                                 Congenital brain cortical malformations                                      TORCH infections( Toxoplasmosis, Others, Rubella Cytomegalovirus Hepatitis C )                                                                Other types of cerebral palsy (athetoid , atonic , ataxic ,  mixed )                                                                               Acute infections (Human Immunodeficiency Virus , Hepatitis C Virus )                                  Hemorrhagic diathesis                                                                                             Severe anemia ( Hemoglobin less than 8 )                              Ventilator dependent pulmonary diseases                              Severe renal dysfunction                                                                           Severe liver dysfunction</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G80</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Cerebral palsy</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group  :  CP patients receiving  ،three  intrathecal injection of 20 millions  allogenic mesenchymal stem cellls derived from umbilical cord ,   prepared by Cell Thec Pharmed Company. Interval of injections is every 2 weeks .  Intrathecal injection will be done under anesthesia via lumbar puncture . After taking 3-5  milliliter of cerebrospinal fluid ,  2 milliliter prepared stem cells will be injected with a syringe . The patient will be admitted for one day for monitoring of probable adverse reactions  . One year followup and evaluation with regular similar rehabilitative therapy will be done .</i_keyword>
      <i_keyword>Control group  : CP  patients without injection , that after insertion of needle into the skin without entering into the cerebrospinal fluid space , needle will be withdrawn without any injection and only with an appearance of simulation of lumbar puncture without the awareness of the patient or their parents. The patient will be admitted one day for monitoring of probable adverse reaction . One year followup and evaluation with regular similar rehabilitative therapy will be done .</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Motor development alteration with GMFM 66 score. Timepoint: Before intervention ,  3 months after first intervention ,6 months after first intervention , 12 months after first intervention. Method of measurement: GMFM 66 score Questionnaire.</prim_outcome>
      <prim_outcome>Change of motor function with GMFCS score. Timepoint: Before intervention ,  3 months after first intervention ,6 months after first intervention , 12 months after first intervention. Method of measurement: GMFCS Questionnaire.</prim_outcome>
      <prim_outcome>Change of motor function according to PEDI  score. Timepoint: Before intervention ,  3 months after first intervention ,6 months after first intervention , 12 months after first intervention. Method of measurement: PEDI Questionnaire.</prim_outcome>
      <prim_outcome>Change of motor function according to MACS  score. Timepoint: Before intervention ,  3 months after first intervention ,6 months after first intervention , 12 months after first intervention. Method of measurement: MACS Questionnaire.</prim_outcome>
      <prim_outcome>Spasticity change of patients according to Ashworth scale. Timepoint: Before intervention ,  3 months after first intervention ,6 months after first intervention , 12 months after first intervention. Method of measurement: Ashworth Questionnaire.</prim_outcome>
      <prim_outcome>Change of quality of life. Timepoint: Before intervention ,  6 months after first intervention , 12 months after first intervention. Method of measurement: CPQOL Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Probable Change of brain lesions. Timepoint: Before intervention , 1 year after first intervention. Method of measurement: Brain Magnetic Resonance Imaging (MRI), Brain Magnetic Resonance Spectroscopy (MRS) , Brain Deep Tensor Imaging (DTI).</sec_outcome>
      <sec_outcome>Number of participants experiencing adverse effects and serious adverse effects. Timepoint: First 24 hours after injection and then any time if occurred. Method of measurement: Questionnaire , parents report and periodic planned clinical evaluations.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>ROYAN stem cell technology Co</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
      <source_name>ROYAN stem cell technology Co</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-02-11</approval_date>
        <contact_name>Tehran University of Medical Sciences</contact_name>
        <contact_address>No 226, Central organization, Ghods Street, Keshavarz Boulvar Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
